A Phase 1, Open-label, Multicenter Study to Assess Safety, Tolerability, PK, and Efficacy of MK-1084 as Monotherapy and as Part of Various Combination Therapies in Participants With KRAS G12C Mutant Advanced Solid Tumors
Latest Information Update: 11 Jul 2024
At a glance
- Drugs MK-1084 (Primary) ; Pembrolizumab (Primary) ; Carboplatin; Cetuximab; Fluorouracil; Folinic acid; Oxaliplatin; Pemetrexed
- Indications Adenocarcinoma; Cervical cancer; Colorectal cancer; Non-small cell lung cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Merck Sharp & Dohme; Merck Sharp & Dohme Corp.
- 04 Apr 2024 According to a Merck media release, preliminary safety and efficacy data from this trial were previously presented at the European Society for Medical Oncology (ESMO) Congress in 2023.
- 28 Feb 2024 Results (As of Aug 4, 2023, n=54) assessing safety and efficacy of MK-1084 in solid tumors and in combination with pembrolizumab in NSCLC presented at the ESMO Targeted Anticancer Therapies Congress 2024
- 20 Jan 2024 Trial design, presented at the 2024 Gastrointestinal Cancers Symposium